Kuros Biosciences AG
SIX:KURN

Watchlist Manager
Kuros Biosciences AG Logo
Kuros Biosciences AG
SIX:KURN
Watchlist
Price: 27.48 CHF -1.01% Market Closed
Market Cap: 1.1B CHF

Kuros Biosciences AG
Total Liabilities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Kuros Biosciences AG
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Kuros Biosciences AG
SIX:KURN
Total Liabilities
CHf32.4m
CAGR 3-Years
29%
CAGR 5-Years
30%
CAGR 10-Years
N/A
ADC Therapeutics SA
NYSE:ADCT
Total Liabilities
$527.9m
CAGR 3-Years
7%
CAGR 5-Years
29%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Total Liabilities
$329.3m
CAGR 3-Years
-6%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Total Liabilities
CHf145.7m
CAGR 3-Years
-22%
CAGR 5-Years
-12%
CAGR 10-Years
-3%
Idorsia Ltd
SIX:IDIA
Total Liabilities
CHf1.6B
CAGR 3-Years
0%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Relief Therapeutics Holding SA
SIX:RLF
Total Liabilities
CHf15.4m
CAGR 3-Years
-37%
CAGR 5-Years
9%
CAGR 10-Years
N/A
No Stocks Found

Kuros Biosciences AG
Glance View

Market Cap
1B CHF
Industry
Biotechnology

Kuros Biosciences Ltd. engages in the discovery, development and prospective commercialization of a new class of biopharmaceutical products that are intended for use in the treatment and prevention of chronic diseases. The company is headquartered in Schlieren, Zuerich and currently employs 58 full-time employees. The company went IPO on 2002-10-29. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The firm has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The firm has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.

KURN Intrinsic Value
36.86 CHF
Undervaluation 25%
Intrinsic Value
Price

See Also

What is Kuros Biosciences AG's Total Liabilities?
Total Liabilities
32.4m CHF

Based on the financial report for Jun 30, 2025, Kuros Biosciences AG's Total Liabilities amounts to 32.4m CHF.

What is Kuros Biosciences AG's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
30%

Over the last year, the Total Liabilities growth was 51%. The average annual Total Liabilities growth rates for Kuros Biosciences AG have been 29% over the past three years , 30% over the past five years .

Back to Top